ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
1,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
3,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
4,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
5,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
6,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
6,2,Urinary tract disorder,Genital and urinary tract disorders NEC,Genitourinary tract disorders NEC,Renal,N
7,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
8,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
9,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
9,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
10,1,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
11,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
12,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
12,2,Stoma obstruction,Stoma complications,Procedural related injuries and complications NEC,Inj&P,N
13,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
14,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
15,1,Hormone-refractory prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
15,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
16,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
17,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
18,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
18,2,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
19,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
19,2,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
20,1,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
20,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
20,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
21,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
22,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
23,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
24,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
25,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
26,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
27,1,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
28,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
28,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
28,3,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
28,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
29,1,Biliary obstruction,Obstructive bile duct disorders (excl neoplasms),Bile duct disorders,Hepat,Y
29,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
29,3,Prostatic specific antigen increased,Cell marker analyses,Cytogenetic investigations and genetic analyses,Inv,N
30,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
31,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
